This therapy may treat neurological and oncological conditions
Evgen, a company developing sulforaphane-based therapies, has revealed that a placebo-controlled, dose-escalating Phase 1/1b clinical trial of SFX-01 was administered to an initial group of healthy volunteers . This treatment is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
This study aims to provide further insight into the pharmacodynamic and pharmacokinetic properties of a novel enteric-coated tablet formulation of SFX-01. We also investigate how sulforaphane released from the candidates engages with key molecular targets.
The new formulation, which replaces the manually-filled capsule prototype formulation, releases sulforaphane into targeted parts of the gut with the goal of predictable release and minimal gastrointestinal side effects. If the SFX-01 works as expected, it is suitable for large-scale testing and commercial supply.
Dr. Huw Jones, CEO of Evgen, explains: We believe this confirms his improved delivery of SFX-01 with the new formulation. ”
“Additionally, as Evgen expands into new indications in oncology and neurodevelopmental disorders, we will gain further insight into how the asset engages with important molecular targets,” he added.
Evgen has already completed three SFX-01 patient trials, including an open-label, positive study in metastatic breast cancer using an experimental capsule formulation. The company’s core technology is sulforadex. This is a method to stabilize and synthesize the natural compound sulforaphane, in addition to novel and proprietary analogues based on sulforaphane.
Sulforaphane has demonstrated potential benefits in neurodevelopmental disorders, oncology, and inflammatory conditions. SFX-01, on the other hand, is the only stabilized sulforaphane suitable for clinical study and approval as an eventual therapeutic.